482308-06-5

Basic information

• Product Name: ASISCHEM A93504
• Synonyms: 3-METHOXY-4-MORPHOLINOANILINE;ASISCHEM A93504;(3-methoxy-4-morpholino-phenyl)amine;3-methoxy-4-(4-morpholinyl)Benzenamine
• CAS NO: 482308-06-5
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.259
• Mol File: 482308-06-5.mol

Chemical Properties

• Boiling Point: 411.054 °C at 760 mmHg
• Flash Point: 202.398 °C
• Appearance: /
• Density: 1.163 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.573
• PKA: 7.56±0.40(Predicted)
• CAS DataBase Reference: ASISCHEM A93504(CAS DataBase Reference)
• NIST Chemistry Reference: ASISCHEM A93504(482308-06-5)
• EPA Substance Registry System: ASISCHEM A93504(482308-06-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 482308-06-5(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Industry:
ASISCHEM A93504 is used as a herbicide and pesticide for its ability to inhibit the enzyme acetolactate synthase, which is crucial for the biosynthesis of branched-chain amino acids in plants. This action leads to the death of the plants, making it an effective tool for controlling unwanted vegetation.
Used in Pharmaceutical Industry:
ASISCHEM A93504 is used as a chemical compound in the development of novel drugs due to its unique structural and functional properties. Its potential applications in this industry are currently being explored, highlighting its importance in the research and development of new pharmaceuticals.

InChI:InChI=1/C11H16N2O2/c1-14-11-8-9(12)2-3-10(11)13-4-6-15-7-5-13/h2-3,8H,4-7,12H2,1H3

Upstream product

• 97459-72-8 4-(2-methoxy-4-nitrophenyl)morpholine 
• 77337-82-7 1-bromo-2-methoxy-4-nitrobenzene 
• 454-16-0 1-fluoro-2-methoxy-4-nitrobenzene 

Downstream Products

• 500544-48-9 C₂₄H₂₄N₆O₂ 
• 1610766-82-9 C₂₆H₃₃N₅O₅ 
• 1574541-74-4 (±)-3-bromo-1-(3-methoxy-4-morpholinophenyl)pyrrolidin-2-one 
• 1574538-36-5 3-(4-cyclopropylphenoxy)-1-(3-methoxy-4-morpholinophenyl)pyrrolidin-2-one 
• 1574538-37-6 3-(4-cyclopropylphenoxy)-1-(3-methoxy-4-morpholinophenyl)pyrrolidin-2-one 
• 1574538-35-4 (±)-3-(4-cyclopropylphenoxy)-1-(3-methoxy-4-morpholinophenyl)pyrrolidin-2-one 
• 1417795-37-9 C₁₆H₁₈IN₃O₂ 
• 1417795-25-5 C₂₄H₂₄N₄O₃ 
• 1417795-23-3 C₂₃H₂₂N₄O₂ 
• 1417795-30-2 C₂₄H₂₄N₄O₃ 
• 1417795-29-9 C₂₄H₂₄F₃N₃O₃ 
• 1417795-28-8 C₂₃H₂₄FN₃O₃ 

Relevant articles and documents

COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS

Provided are compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.

QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

A class of FLT3 kinase inhibitors, preparation and application thereof

The invention relates to a class of FLT3 kinase inhibitors, preparation and application thereof, wherein specifically the compound has a structure represented by a formula (I), and all groups and substituents are defined in the specification. The invention also discloses a preparation method of the compound, and application of the compound in inhibition of FLT3.

VEGFR TYROSINE KINASE INHIBITORS

Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.

IMIDAZOPYRAZINE SYK INHIBITORS

Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suf-fering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of an imidazopyrazine compound effective to reduce signs or symptoms of the disease or dis-order are provided.

Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors

The insulin-like growth factor-1 receptor (IGF-1R) plays an important role in the regulation of cell growth and differentiation, and in protection from apoptosis. IGF-1R has been shown to be an appealing target for the treatment of human cancer. Herein, w

COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES

The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P2Y12 purinoreceptor blocker, to a process for producing these combinations and to the use thereof as medicaments, in particular for the prophylaxis and/or treatment of thromboembolic disorders.

MICROANGIOPATHY TREATMENT AND PREVENTION

The present invention relates to the use of selective factor Xa inhibitors, in particular of oxazolidinones of the formula (I) for the treatment and/or prophylaxis of microangiopathies and also their use for the production of medicaments for the treatment and/or prophylaxis of microangiopathies.

Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders

The present invention relates to combinations of A) oxazolidinones of the formula (I), with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.